Citadel Advisors’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $36.9M | Buy |
513,531
+203,754
| +66% | +$11.6M | 0.01% | 1649 |
|
|
2025
Q4 | $13.1M | Sell |
309,777
-51,296
| -14% | -$2.87M | ﹤0.01% | 2885 |
|
|
2025
Q3 | $20.5M | Buy |
+361,073
| New | +$12M | ﹤0.01% | 2297 |
|
|
2025
Q2 | – | Sell |
-32,746
| Closed | -$368K | – | 14210 |
|
|
2025
Q1 | $334K | Buy |
32,746
+6,277
| +24% | +$82K | ﹤0.01% | 9345 |
|
|
2024
Q4 | $369K | Sell |
26,469
-437,196
| -94% | -$7.71M | ﹤0.01% | 9236 |
|
|
2024
Q3 | $9.04M | Hold |
463,665
| – | – | ﹤0.01% | 3070 |
|
|
2024
Q2 | $8.62M | Buy |
463,665
+250,751
| +118% | +$5.28M | ﹤0.01% | 2967 |
|
|
2024
Q1 | $2.98M | Sell |
212,914
-162,086
| -43% | -$1.7M | ﹤0.01% | 4796 |
|
|
2023
Q4 | $3.18M | Hold |
375,000
| – | – | ﹤0.01% | 4539 |
|
|
2023
Q3 | $3.35M | Sell |
375,000
-271,910
| -42% | -$2.62M | ﹤0.01% | 4293 |
|
|
2023
Q2 | $5.58M | Buy |
646,910
+456,039
| +239% | +$4.86M | ﹤0.01% | 3486 |
|
|
2023
Q1 | $2.01M | Buy |
190,871
+65,379
| +52% | +$1.98M | ﹤0.01% | 5359 |
|
|
2022
Q4 | $4.25M | Buy |
125,492
+45,148
| +56% | +$2.19M | ﹤0.01% | 4127 |
|
|
2022
Q3 | $3.86M | Buy |
80,344
+48,454
| +152% | +$2.88M | ﹤0.01% | 4315 |
|
|
2022
Q2 | $1.82M | Sell |
31,890
-35,416
| -53% | -$2.23M | ﹤0.01% | 5732 |
|
|
2022
Q1 | $5.44M | Buy |
67,306
+55,224
| +457% | +$8.17M | ﹤0.01% | 4007 |
|
|
2021
Q4 | $2.45M | Buy |
12,082
+5,733
| +90% | +$1.24M | ﹤0.01% | 5783 |
|
|
2021
Q3 | $1.71M | Sell |
6,349
-1,288
| -17% | -$310K | ﹤0.01% | 6765 |
|
|
2021
Q2 | $1.97M | Buy |
7,637
+681
| +10% | +$188K | ﹤0.01% | 6666 |
|
|
2021
Q1 | $2.09M | Buy |
6,956
+4,902
| +239% | +$1.53M | ﹤0.01% | 6286 |
|
|
2020
Q4 | $524K | Sell |
2,054
-17,286
| -89% | -$4.47M | ﹤0.01% | 8061 |
|
|
2020
Q3 | $4.81M | Sell |
19,340
-13,855
| -42% | -$4.36M | ﹤0.01% | 3223 |
|
|
2020
Q2 | $11.5M | Buy |
33,195
+1,490
| +5% | +$465K | ﹤0.01% | 2062 |
|
|
2020
Q1 | $8.49M | Buy |
31,705
+16,855
| +114% | +$5.21M | ﹤0.01% | 2050 |
|
|
2019
Q4 | $4.81M | Buy |
14,850
+4,739
| +47% | +$1.37M | ﹤0.01% | 3131 |
|
|
2019
Q3 | $2.76M | Buy |
10,111
+2,590
| +34% | +$950K | ﹤0.01% | 3983 |
|
|
2019
Q2 | $4.01M | Sell |
7,521
-12,784
| -63% | -$6.41M | ﹤0.01% | 3423 |
|
|
2019
Q1 | $10.2M | Sell |
20,305
-14,707
| -42% | -$8.72M | 0.01% | 2049 |
|
|
2018
Q4 | $17.3M | Buy |
35,012
+29,796
| +571% | +$18M | 0.01% | 1355 |
|
|
2018
Q3 | $4.77M | Sell |
5,216
-22,990
| -82% | -$19.6M | ﹤0.01% | 3074 |
|
|
2018
Q2 | $20.7M | Buy |
28,206
+28,067
| +20,192% | +$32.4M | 0.01% | 1282 |
|
|
2018
Q1 | $222K | Sell |
139
-1,796
| -93% | -$2.31M | ﹤0.01% | 7192 |
|
|
2017
Q4 | $1.73M | Sell |
1,935
-5,995
| -76% | -$3.55M | ﹤0.01% | 3829 |
|
|
2017
Q3 | $2.85M | Sell |
7,930
-550
| -6% | -$172K | ﹤0.01% | 2984 |
|
|
2017
Q2 | $2.49M | Buy |
8,480
+4,836
| +133% | +$1.4M | ﹤0.01% | 2883 |
|
|
2017
Q1 | $1.28M | Buy |
3,644
+2,902
| +391% | +$652K | ﹤0.01% | 3632 |
|
|
2016
Q4 | $137K | Sell |
742
-273
| -27% | -$55.5K | ﹤0.01% | 6549 |
|
|
2016
Q3 | $261K | Buy |
+1,015
| New | +$261K | ﹤0.01% | 5905 |
|
|
2015
Q3 | – | Sell |
-726
| Closed | -$128K | – | 9124 |
|
|
2015
Q2 | $136K | Sell |
726
-2,035
| -74% | -$350K | ﹤0.01% | 6752 |
|
|
2015
Q1 | $455K | Buy |
2,761
+2,441
| +763% | +$502K | ﹤0.01% | 5041 |
|
|
2014
Q4 | $75K | Sell |
320
-24,823
| -99% | -$5.31M | ﹤0.01% | 6897 |
|
|
2014
Q3 | $4.55M | Buy |
25,143
+16,022
| +176% | +$3.07M | ﹤0.01% | 2073 |
|
|
2014
Q2 | $1.75M | Buy |
+9,121
| New | +$1.61M | ﹤0.01% | 2860 |
|
|
2014
Q1 | – | Sell |
-3,206
| Closed | -$634K | – | 7958 |
|
|
2013
Q4 | $546K | Buy |
+3,206
| New | +$517K | ﹤0.01% | 3912 |
|
|
2013
Q3 | – | Sell |
-8,158
| Closed | -$1.51M | – | 6819 |
|
|
2013
Q2 | $1.41M | Buy |
+8,158
| New | +$1.25M | ﹤0.01% | 2827 |
|
Other funds holding NKTR
BI
TSC
VCM
PM
AC
Citadel Advisors's NKTR Position: Q1 2026 in Review
Citadel Advisors increased its Nektar Therapeutics (NKTR) stake by 66% in Q1 2026, buying an estimated $11.6M and bringing the position to 513,531 shares worth $36.9M. The position accounts for 0.01% of the portfolio, ranked #1649.
Citadel Advisors first reported a position in NKTR in Q2 2013 and has held it in 45 quarters since. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.
- Citadel Advisors held 513,531 shares of Nektar Therapeutics worth $36.9M as of Q1 2026.
- Citadel Advisors bought 203,754 Nektar Therapeutics shares in Q1 2026, an estimated $11.6M.
- Nektar Therapeutics made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1649 holding.
- Citadel Advisors first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 45 quarters since.
- 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.